Clinical Trials Sponsored by Inspiration Biopharmaceuticals, Inc.

Total 122 results

Spiration, Inc.

Completed

REACH SVS Control Patient Cross-Over Study

Emphysema

China
Spiration, Inc.

Completed

IBV Valve System for the Treatment of Prolonged Air Leak Under HDE H060002 - Post Approval Study (HUD-PAS)

Prolonged Air Leak

United States
Spiration, Inc.

Completed

Pilot Study of the Spiration IBV™ System

Emphysema

United States
Spiration, Inc.

Completed

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema (IBV®Valve)

Emphysema | COPD

United States
Spiration, Inc.

Completed

European Multi-center Post Market Study of the IBV Valve System (IBV)

Chronic Obstructive Pulmonary Disease

Spain, Germany, Italy, Austria, Belgium, United Kingdom
Heidelberg University
Spiration, Inc.

Unknown

Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study

Pulmonary Emphysema

Germany
Gracell Biopharmaceuticals, Inc.

Recruiting

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States
NGM Biopharmaceuticals, Inc

Completed

A Study of NGM621 in Participants With Geographic Atrophy (CATALINA)

Geographic Atrophy

United States
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

ST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
NGM Biopharmaceuticals, Inc

Completed

Study of NGM621 in Participants With Geographic Atrophy

Geographic Atrophy

United States
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PROMISE 1)

Migraine Disorders

United States, Georgia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Impaired Renal Function

United States
Alder Biopharmaceuticals, Inc.

Completed

Safety, Efficacy and Pharmacokinetics of ALD403

Migraine

United States
NGM Biopharmaceuticals, Inc

Completed

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Diabetes Mellitus

Australia
RegeneRx Biopharmaceuticals, Inc.

Completed

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Pressure Ulcers

United States
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function

United States
NGM Biopharmaceuticals, Inc

Completed

Study of NGM395 in Adult Participants

Obesity | NAFLD

Australia
Alder Biopharmaceuticals, Inc.

Completed

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)

Migraine Disorder

United States
NGM Biopharmaceuticals, Inc

Completed

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Cachexia

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of NGM313 in Obese Participants

Obese

United States
NGM Biopharmaceuticals, Inc

Completed

Phase 1 Study of NGM313 in Healthy Adult Participants

Obesity

Australia
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Myocardial Infarction | Myocardial Ischemia

United States
AgoneX Biopharmaceuticals, Inc.

Not yet recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

Migraine Prophylaxis
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
NGM Biopharmaceuticals, Inc

Active, not recruiting

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Melanoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostate Cancer | Head Neck Squamous Cell Carcinoma

United States
NGM Biopharmaceuticals, Inc

Terminated

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

SARS-CoV-2 Infection

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Healthy Male

United States
NGM Biopharmaceuticals, Inc

Completed

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Alder Biopharmaceuticals, Inc.

Completed

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2)

Migraine Disorders

United States, Belgium, Italy, Spain, United Kingdom, Germany, Hungary, Georgia, Slovakia, Russian Federation, Ukraine, Denmark, Czechia
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Chronic Migraine

Migraine Disorders

United States, Georgia, Australia, New Zealand
NGM Biopharmaceuticals, Inc

Completed

Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

United States, France, Netherlands, United Kingdom
NGM Biopharmaceuticals, Inc

Completed

Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

Functional Constipation

United States
RegeneRx Biopharmaceuticals, Inc.

Terminated

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Epidermolysis Bullosa
Alder Biopharmaceuticals, Inc.

Completed

Safety Tolerability and Pharmacokinetics of ALD403

Migraine Disorders

Australia
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Osteoarthritis, Knee

Australia, United States
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Pompe Disease

United States
Paradigm Biopharmaceuticals USA (INC)

Active, not recruiting

An Observational Follow-up Study to Evaluate Duration of Treatment Effect of Pentosan Polysulfate Sodium in Participants With Knee Osteoarthritis Pain

Osteoarthritis, Knee

United States, Australia
Ohio State University
Spiration, Inc.

Withdrawn

Spiration IBV® Valve System and Spiration Airway Sizing Kit

Management of BPF (Bronchopleural Fistulae)

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

NAN-101 in Patients With Class III Heart Failure (NAN-CS101)

Cardiovascular Diseases | Heart Failure | Heart Failure, Diastolic | Congestive Heart Failure | Heart Failure, Systolic | Heart Disease, Ischemic | Heart Failure，Congestive | Heart Arrhythmia | Heart; Complications

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (GenePHIT)

Congestive Heart Failure

United States
Asklepios Biopharmaceutical, Inc.

Recruiting

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Muscular Dystrophy | Limb Girdle Muscular Dystrophy | LGMD2I | LGMD | Limb-Girdle Muscular Dystrophy Type 2 | LGMD2 | FKRP | FKRP Mutation | Fukutin Related Protein

United States
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Parkinson's Disease | Multiple System Atrophy | Multiple System Atrophy, Parkinson Variant

United States, Poland
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Advanced Solid Tumor | Advanced Gastric Carcinoma | Advanced Cholangiocarcinoma | Advanced Lung Cancer

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Oncology | CTLA4 Haploinsufficiency

China
Day One Biopharmaceuticals, Inc.

Available

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Low-grade Glioma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
Sichuan Clover Biopharmaceuticals, Inc.

Terminated

A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis

Peritoneal Carcinomatosis

China
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

Blood Loss, Surgical

United States
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures

Peripheral Vascular Disease

United States, United Kingdom
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico

Clinical Trials Sponsored by Inspiration Biopharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations